An observational study in Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) and Lung Cancer (Diagnosis), sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Small Cell Lung Carcinoma with a site in Austria — 8 open to participants now, 19 under way, 12 of them phase 3. Small Cell Lung Carcinoma · Austria.
Among the 39 studies in Small Cell Lung Carcinoma with a site in Austria, this one is one of 4 that started in 2025, is one of 3 observational ones, reaches primary completion later than 18 of the 18 other live ones, and was the 38th registered.
1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →8 of the 39 studies in Small Cell Lung Carcinoma with a site in Austria are open now. Recruiting first, the newest first:
AbbVie · Sites in Austria, United States, Belgium and 7 more countries
Ages 18+
Boehringer Ingelheim · Sites in Austria, United States, Argentina and 39 more countries
Ages 18+
Medical University of Graz · Sites in Austria
Ages 18–75
Zai Lab (Shanghai) Co., Ltd. · Sites in Austria, United States, Belgium and 12 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Austria, United States, Argentina and 23 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 23
First in 2001; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 137 across 144 observational studies indexed under Small Cell Lung Carcinoma.
Median enrollment 497 across the 36 interventional studies, 500 across the 3 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 39 have an industry lead sponsor. The 10 most frequent:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest is the lead sponsor of 64 studies on the registry; 17 are open to participants now.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest has 2 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Small Cell Lung Carcinoma with a site in Austria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06646276Phase 3Bristol-Myers SquibbA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | 2027-08-17 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Small Cell Lung Carcinoma with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.
The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.
The study includes adult patients with resectable NSCLC (perioperative setting), locally advanced or metastatic NSCLC (1st/2nd line), or extensive-stage SCLC (1st line) who are receiving Tislelizumab according to its approved indications. Approximately 240 patients will be enrolled across about 38 sites.
ReWoLuTe builds on strong clinical evidence from phase III RATIONALE studies and seeks to understand the drug's performance in a broader, more heterogeneous population typically underrepresented in clinical trials. Data collection follows routine clinical practice, including regular assessments during treatment and long-term follow-up for up to five years.
Endpoints include overall survival (primary) and multiple secondary measures such as PFS, DFS, EFS, treatment duration, HRQoL deterioration, and adverse event profiles. Safety data-including immune-mediated events-will be systematically captured and reported according to regulatory requirements.
The study is scheduled to run up to 2033, with interim analyses planned after enrollment and follow-up milestones. Optional archival tissue collection will support accompanying translational research.
The ReWoLuTe study enrolls patients in Germany and Austria of both sexes and ages over 18 years. All patients are diagnosed with resectable non-small cell lung carcinoma (NSCLC) in the perioperative curative setting OR locally advanced or metastatic NSCLC in the 1st or 2nd line therapy setting OR small cell lung carcinoma (SCLC) in the 1st line therapy setting, with no local curative therapy available AND treated with a tislelizumab-based therapy according to label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has a confirmed resectable Non-small cell lung cancer in stage II-IIIA with high risk of recurrence according to the 8th edition of the following AJCC staging criteria and is eligible for an R0 resection with curative intent and treatment with Tislelizumab in and adjuvant setting:
Tumors with one or more separate nodules in the same lobe as the primary lung carcinoma.
OR
Patient has a histologically confirmed locally advanced or lung carcinoma of one of the following subtypes and is eligible for treatment with Tislelizumab in an approved indication:
NOTE:
Patients who have already received 1-2 cycles of therapy are still eligible for enrollment into the NIS. Patients who intended to be treated in the curative setting and had to switch before the start of an adjuvant treatment to the palliative setting or BSC (e.g. due to progress or other reasons), will not be excluded from study.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study includes adult lung cancer patients with resectable NSCLC (perioperative setting), locally advanced or metastatic NSCLC (1st/2nd line), or extensive-stage SCLC (1st line) who are receiving Tislelizumab according to its approved indications.
Overall survival (OS)
Overall survival (OS) is used as measurement to further characterize the effectiveness of tislelizumab therapy in real-world lung cancer patients.
Time frame: From first Tislelizumab administration up to a maximum of 84 months
Duration of treatment (DoT)
Duration of treatment (DoT), defined as time from date of first Tislelizumab administration to the date of treatment discontinuation due to any cause.
Time frame: From enrolment up to a maximum of 84 months.
Progression-free survival (PFS)
Progression-free survival (PFS), defined as time from date of first Tislelizumab administration to the date of progression according to the attending physician's judgement or death due to any cause, whichever occurs first.
Time frame: From first Tislelizumab administration up to a maximum of 84 months
Disease-free survival (DFS)
Disease-free survival (DFS), defined as the time from the date of resection until the first documented disease-related event or death from any cause, whichever occurs first. Disease-related events include local recurrence, regional recurrence, distant metastasis, or the occurrence of a second primary malignancy.
Time frame: From date of resection up to a maximum of 84 months
Event-Free Survival (EFS)
Event-Free Survival (EFS) is defined as the time from date of first Tislelizumab administration until the occurrence of any of the following events: disease progression prior to surgery that precludes curative resection, failure to undergo curative-intent surgery for any disease-related reason, postoperative disease recurrence (local, regional, or distant), or death from any cause.
Time frame: From first Tislelizumab administration up to a maximum of 84 months
Tislelizumab treatment dose in lung cancer patients
Total treatment dose across lines of therapy in patients treated with Tislelizumab.
Time frame: From enrolment up to a maximum of 84 months
Tislelizumab treatment frequency in lung cancer patients
Treatment frequency assessed as numbers of cycles across lines of therapy in patients treated with Tislelizumab.
Time frame: From enrolment up to a maximum of 84 months
Tislelizumab duration of treatment delays in lung cancer patients
Duration of of treatment delays across lines of therapy in patients treated with Tislelizumab.
Time frame: From enrolment up to a maximum of 84 months
Tislelizumab temporary treatment interruptions in lung cancer patients
Treatment interruptions across lines of therapy in patients treated with Tislelizumab
Time frame: From enrolment up to a maximum of 84 months
Time to Health-Related Quality of Life (HR-QoL) Deterioration as assessed by EORTC QLQ-C30
Time to Health-Related Quality of Life (HR-QoL) Deterioration (TTD), measured from start of Tislelizumab treatment to the first ≥10 points decrease of HR-QoL score compared to baseline HR-QoL score with HR-QoL scores derived from EORTC QLQ-C30
Time frame: From start of Tislelizumab treatment up to a maximum of 84 months
Time to Health-Related Quality of Life (HR-QoL) Deterioration as assessed by EORTC QLQ-LC13
Time to Health-Related Quality of Life (HR-QoL) Deterioration (TTD), measured from start of Tislelizumab treatment to the first ≥10 points decrease of HR-QoL score compared to baseline HR-QoL score with HR-QoL scores derived from EORTC QLQ-LC13
Time frame: From start of Tislelizumab treatment up to a maximum of 84 months
Adverse event profiles
AE frequency, listed with severity, drug-relation, and management of the following groups of AEs: Selected AEs (immune-mediated pneumonitis, colitis, hepatitis, nephritis/renal dysfunction, endocrinopathies, and rash), other immune-mediated AEs (imAEs), other treatment-related AEs, fatal AEs.
Time frame: From enrolment up to a maximum of 84 months
Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2032, 84 months after the start.
Of 62 observational studies under Small Cell Lung Carcinoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 47. This study's planned 84 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest